Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
The drug industry is having its own DeepSeek moment
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
WISH-TV on MSN4d
Lilly's profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales
Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...
FiercePharma4d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Nature5d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...